anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for efficiently obtaining a liposome without using an organic solvent, to provide a stable chitosan-modified liposome using the method and to provide applications of the liposome obtained by the method for production.  &lt;P&gt;SOLUTION: A suspension in which the liposome is dispersed in an aqueous phase is obtained as follows. A phospholipid and/or a glycolipid are used as a membrane lipid and one or more kinds of hydrophilic medicinally effective ingredients and/or lipophilic medicinally effective ingredients are used as an included substance. Water, the included substance and a low- or a high-molecular modifying substance for modifying the liposome and/or an aqueous solution prepared by dissolving or dispersing one or more kinds of dissolving adjuvants therein and gaseous carbon dioxide are sealed in a pressure vessel and stirred while being held at 0-100°C temperature under 30-500 atm pressure for 0.5-5 h. Thereby, an emulsion of CO&lt;SB&gt;2&lt;/SB&gt;/H&lt;SB&gt;2&lt;/SB&gt;O in which the emulsion of the gaseous carbon dioxide is dispersed in water is obtained. The gaseous carbon dioxide is taken out of the pressure vessel to afford a suspension in which the liposome is dispersed in the aqueous phase remaining in the pressure vessel or in the aqueous phase discharged while being accompanied with the carbon dioxide. The method for producing the liposome and the applications of the liposome obtained by the method for production are provided.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE: To obtain a fat emulsion, containing a medicine and improved in stability by carrying out the sterilizing treatment according to a high-pressure heat-treating method, etc., and then providing a state of substantially no oil droplet in the fat emulsion containing a pharmacodynamically effective ingredient, an oily ingredient, a phospholipid and water, etc. CONSTITUTION: This fat emulsion containing a medicine without substantially containing oil droplets or producing the oil droplets after sterilizing treatment is prepared by mixing, e.g. a prescribed amount of an oily ingredient (e.g. soybean oil) with a phospholipid and an additive under heated conditions or at normal temperatures using a usually used homogenizer (e.g. a high-pressure jetting type or an ultrasonic homogenizer), preparing a homogeneous oily phase, then adding a required amount of water thereto, further homogenizing the resultant mixture with a homogenizer, preparing an oil-in-water type emulsion and then carrying out the sterilizing treatment according to high-pressure heat treatment. The fat emulsion is especially effective for a large capacity, especially &gt;=5ml capacity. The fat emulsion containing the medicine is parenterally administered by injection, etc., and intravenous injection is especially preferred.
NEW MATERIAL:A DNA having a synthetic gene for the expression of human epidermal growth factor (hEGF) of formula. USE:hEGF has the activities to suppress the secretion of gastric acid and promote the proliferation of epidermic cell. The former activity enables the use of the substance as a remedy for duodenal ulcer, and the former activity suggests the possibility of clarifying the canceration mechanism. PREPARATION:The objective hEGF consists of a DNA coding a protein other hEGF and starting from the initiation codon ATG and attached to the 5&#39;-terminal of the synthetic gene of hEGF, and a DNA coding a protein other than hEGF and attached to the 3&#39;-terminal of the hEGF-synthesis gene terminated with the termination codon (e.g. TAG) or starting from the initiation codon ATG, and is terminated with a termination codon (e.g. TAG).
NEW MATERIAL:A compound shown by the formula I (R&lt;1&gt; is aryl, heteroaryl, alkyl, or cycloalkyl; Y is S, or O; X is halogen) or its salt. EXAMPLE:5-{[2-(4-Chlorophenyl)-5-(2-furyl)-4-thiazolyl]methyl}tetrazole. USE:A drug having cholesterol-lowering action. PREPARATION:A novel azole compound shown by the formula II is reacted with ammonium azide shown by the formula NH4N3, to give a compound shown by the formula I. The reaction is carried out in an inert solvent (e.g., DMF, dioxane, etc.) at 100-150 deg.C. The compound shown by the formula II is obtained by reacting a 3-acylamino-4-oxobutyric ester shown by the formula III with a sulfurizing condensation agent or a dehydrating agent in an inert solvent to give a compound shown by the formula IV, reacting the reaction product with ammonia to give an azolacetic acid amide shown by the formula V, and reacting the compound shown by the formula with a dehydrating agent.
PROBLEM TO BE SOLVED: To obtain the subject low-viscosity composition having a low plastic fluidity without sagging at the time of coating, further having a sufficient mechanical strength and useful as a restorative material for dental use, especially a material for covering a dental neck and a dental root parts by including a filler, a polymerizable monomer and a polymerization initiator. SOLUTION: This composition is obtained by including (A) a filler (e.g. a borosilicate glass), (B) a polymerizable monomer (e.g. methyl methacrylate or acrylic acid) and (C) a polymerization initiator (e.g. t-butyl hydroperoxide or N-methylaniline) and has 3-300 P viscosity and &lt;=1 mm plastic flow distance. The composition preferably contains 100 pts.wt. of the ingredient A having 0.05-1 μm average particle diameter, 30-100 pts.wt. of the ingredient B and 0.003-5 pts.wt. of the ingredient C. The ingredient A is preferably a spherical inorganic filler and 0.1-10 pts.wt. of a particulate filler having &lt;0.05 μm average particle diameter is preferably contained therein.
PROBLEM TO BE SOLVED: To obtain an activator of heparin cofactor II comprising a specific polymer consisting essentially of a conjugated diene-based monomer unit, capable of being readily synthesized and always having a steady activating activity of the heparin cofactor II. SOLUTION: This activator of heparin cofactor II comprises a conjugated diene-based (co)polymer containing &gt;=4mmol/g, e.g. 5.0-7.5mmol/g sulfo group and/or its salt and having &gt;=1,000, e.g. 2,000-50,000 weight average molecular weight. Moreover, the (co)polymer is obtained, e.g. by polymerizing the conjugated diene and optionally other monomers (e.g. styrene) in the presence of a free radical polymerization initiator such as hydrogen peroxide at 0-130 deg.C and thereafter sulfonating the obtained conjugated diene-based (co)polymer by using only sulfuric anhydride.
PROBLEM TO BE SOLVED: To obtain a hair grower excellent in depilation-preventive effect and hair growing effect, containing a combination of specific plant extract(s) with an amine oxide. SOLUTION: This hair grower contains 0.005-20wt.%, on a dry basis, of an extract from Arnica momtana L. and 0.0001-20wt.% of an amine oxide of the formula (R&lt;1&gt; is a 2-24C alkyl; R&lt;2&gt; is methyl or hydroxyethyl; A is monoxyethylene; (n) is 0-5) (e.g. N,N-dihydroxymethyl-2-dodecylamine oxide). The extract is obtained from the flower of the corresponding plant. The extractant to be used is an organic solvent. This hair grower is effective for treating/ preventing depilation, being administered percutaneously, for example, through direct coating or spraying on the skin; its daily dose is 0.01-100mg/kg for adult in one to four portions per day.
Methods for the preparation and use of a biological delivery system are disclosed. The method of preparation includes the loading of a non-biological material into a biostructure having a load-bearing structure. The method also includes the removal of some of the biostructure&#39;s contents and the loading of a non-biological material into the biostructure. The biostructure is biologically compatible with the host, and preferably is derived from the host, the host&#39;s species or a related species. The loaded biostructure is used directly, or it can be targeted to specific cells, tissues and/or organs within a host. The targeted biostructure can be used to deliver the non-biological material to a specified tissue, organ or cell within a host for diagnostic, therapeutic or other purposes.
The present application provides methods and compositions for treating and preventing disease associated with polyglutamine protein expansion. For example, the application provides peptoid compounds that selectively bind polyglutamine expanded polypeptides. Methods for using such compounds for treatment, prevention and detection of polyglutamine expansion disorders, such as Huntington&#39;s disease, are likewise provided. In addition, methods and compositions for treating and preventing neuronal disorders linked to pathogenic protein aggregation are disclosed. For example, the application provides peptoid compounds that selectively bind to Αβ42. Methods for using such compounds for treatment and prevention of symptoms of Alzheimer&#39;s disease are likewise provided.
&lt;P&gt;PROBLEM TO BE SOLVED: To efficiently, safely and inexpensively dissolve carbon dioxide, which is generated from a carbon dioxide generating bath agent, into bathtub water.  &lt;P&gt;SOLUTION: A carbon dioxide diffusing apparatus includes a carbon dioxide bath agent dissolving part 2; and a carbon dioxide diffusing device part 1 having micropores. The bubble of the carbon dioxide is made to be very small by the micropores 3 arranged between the dissolving part 2 and the diffusing device part 1 and the micropores 4 arranged in the diffusing apparatus part. Then the bubble of the carbon dioxide is made to be very small. The area where the carbon dioxide contacts the bathtub water is drastically enlarged and contact time is prolonged. The device is stably arranged in the bathtub so as to prevent floating-up owing to the circumferential bubbles of the bath agent and to allow the bath agent to continuously diffuse the carbon dioxide to the end. Accordingly, the carbon dioxide is efficiently dissolved in the bathtub water. When different bath agents such as herbs or emulsifiers are set, pleasure in bathing is increased. When pressure is increased by the generation of the carbon dioxide, excessive gas is discharged from a bathtub water intake hole 5 so as to avoid danger.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Provided are liposomes including a lipid membrane enclosing an intraliposomal compartment. The liposomes may encapsulate an iron complex, including an iron moiety and a macromolecule, in the intraliposomal compartment. The liposomes may additionally have a targeting moiety associated with the liposomal membranes. The targeting moiety may be exposed at the liposome&#39;s outer surface. The liposomes exhibit an immunomodulatory effect or anti-cancer effect depending on the molar ratio between the lipids forming the lipid membrane and the iron complex. As such, the liposomes can be used to treat types of inflammation, particularly inflammations that are not associated or caused by infection or be used to treat cancer. Further provided are compositions including the disclosed liposomes, methods of using and kits including the liposomes.
267,520. Parke Davis &amp;. Co., (Assignees of Ferry, N. S.). March 15, 1926, [Convention date]. Antitoxins, toxins, vaccines, and immunizing and like serums; bacteria, cultivating.-A microorganism (streptococcus morbilli) specific to measles is obtained by inoculating blood from a measles patient into a sterilized medium consisting of brain tissue and liver broth or liver infusion, transferring the culture obtained to whole-blood agar, and isolating streptococci only from those colonies producing a green halo. The organism is a Gram positive, aerobic streptococus, but may appear as a diplocoocus. Toxin is obtained by inoculating a medium such as 0.2 per cent glucose broth with a pure culture, and incubating for several days. Germ-free toxin may be obtained by filtration, or a toxin containing the living or killed organisms may be prepared. The toxin is standardized by means of the skin test, and may be employed for preventive immunization, for skin tests to determine susceptibility to measles, and for the production of antitoxin. An organism may be tested for identity with the specific measles streptococcus by determining the capacity of its sterile toxin, prepared in the above manner, to give characteristic skin reactions and to be neutralized in this respect by admixture with measles convalescent serum. Antitoxin is prepared by injecting a horse with increasing doses of toxin, whether germ-free or containing living or killed organisms, and concentrating, refining, and standardizing the serum.
PURPOSE:The titled cosmetic, containing phosphate ester of a polyoxyalkylene hardened castor oil, capable of remaining on the hair even after washing away, and having good finish feeling, e.g. moistness and luster, and residual perfume effect. CONSTITUTION:A hair cosmetic containing preferably 0.1-10wt%, more preferably 0.3-7wt%, phosphate ester of a polyoxyalkylene hardened castor oil as an active constituent. As for another optional constituent, a surfactant, e.g. a benzenesulfonate salt, in an amount of usually 1-30wt% and a solvent, perfume, germicide, etc. are incorporated therein. The phosphate ester is synthesized by heating a polyoxyalkylene hardened castor oil of the formula (a, b and c are integers &gt;=1, preferably a+b+c is 10-40; R is H or methyl) to 60 deg.C, adding phosphorus pentoxide thereto with stirring, and maturing the mixture at 60 deg.C for 3hr.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for determining an antibody specific profile in an individual, and to provide a means and a method for determining an antigen or an epitope specific profile.  &lt;P&gt;SOLUTION: A specific profile clarifies an individual immunoreaction to a plurality of antigens and/or epitopes such as an autoantigen, an allergen, a graft antigen. The antibody specific profile is determined by bonding to an array of a patient sample including an antibody. The array includes an antigen and an epitope. Further, it is used for either development of diagnosis and treatment individuated or by gene of an immune related disease including an autoimmune disease, allergy and graft rejection.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a portable and disposable inhalation kit for aromatherapy capable of providing a therapy immediately.  &lt;P&gt;SOLUTION: The kit comprises a vial (14) having a capacity of approximately 2 ml prefilled with one application of predetermined amount of preblended and diluted essential oil, a conical mask (10) of paper fiber to which the blended oil is applied, and a heavyweight paper folder (20) for holding both the mask and the vial. At use, the content of the vial is dispersed and attached onto the outer surface of the mask. The mask is then worn over a user&#39;s nose and mouth and the user inhales the vapor for twenty to thirty minutes to enhance the user&#39;s mood and/or condition. The kit is small enough to carry in a glove compartment of an automobile, a backpack, a purse or a pocket. Because the kit does not use an electric source for administration, it is convenient to use at any time or in any location.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PROBLEM TO BE SOLVED: To obtain a cosmetic, having high beautifying effect and excellent in health promoting effect on the skin by compounding an extract of leaves of Ginkgo biloba. SOLUTION: This cosmetic contains ferrous ferric salt solution and an extract of leaves of Ginkgo biloba, which are complexed in a raw material of the cosmetic. The ferrous ferric salt solution is a liquid obtained by adding an active substance formed from ferric chloride through a chemical treatment and extremely small quantity of NaCl into water to prepare a liquid and diluting the resultant liquid with 10&lt;5&gt; to 10&lt;6&gt; times water. The ferrous ferric salt solution has extremely small quantity of ferrous ferric salt which is finely dispersed in water, and has large surface tension and osmotic pressure. When the ferrous ferric salt solution is used after diluted with water, it strengthens phagocytic function of leukocytes and neutrophiles, enhances immunity and prevents senility in an animal, and activates leaves and flowers in a plant.  Further, the salt solution is effective for bacteria proofing and preventing replant failure. The extract of leaves of Ginkgo biloba has vasodilation activity, improving effect on peripheral blood flow, active oxygen-removing effect, etc. By its synergistic effect with a ferrous ferric salt solution which is free from toxic substance and has activity to make cells fresh, the extract of leaves of Ginkgo biloba exhibits excellent humectant and softening effects on the skin and preventing effect on senility such as the spots, freckles and wrinkle.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor having high inhibiting actions on cancer metastasis and reduced in adverse effects by using L-ascorbic acid tetra-fatty acid ester as an active ingredient. SOLUTION: This inhibitor contains L-ascorbic acid tetra-fatty acid ester (e.g. L-ascorbyl tetraisopalmitate which is a tetraester of L-ascorbic acid with a fatty acid (e.g. 2-hexyldecanoic acid, undecylenic acid or palmitoleic acid) as an active ingredient. The active ingredient is preferably included in an amount of 0.001-100 wt.% in a preparation or a composition. The daily dose of the inhibitor for an adult based on 1 kg body weight is preferably 0.001-8,500 mg expressed in terms of the amount of the active ingredient in the case of oral administration, suppository administration, a preparation for external use, etc., and preferably 0.025-200 mg expressed in terms of the amount of the active ingredient in the case of intravenous injection and drip infusion administered in one to divided several portions.  The inhibitor is useful for malignant melanoma, cancer of digestive organs, esophageal carcinoma, Kaposi&#39;s sarcoma, etc.
Oral non-steroidal anti inflammatory drugs (NSAIDs) are not an effective treatment of Alzheimer&#39;s disease, because the brain dose is too low. Nasal delivery of NSAIDs such as ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen, which inhibit the enzymes cyclooxygenase-1 (cox-1) and cox-2, are used to prevent and/or treat Alzheimer&#39;s disease, a low grade brain inflammation. The large amount of nasal NSAIDs (e.g., ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen) that reaches the brain far exceeds that from an oral dose. Low-molecular-weight lipophilic drugs, such as ibuprofen, naproxen, indomethacin, diclofenac, and flurbiprofen, are readily absorbed into the brain by the intranasal route. Alzheimer&#39;s starts in the entorhinal cortex, which is closely connected to the olfactory nerves, and spreads anatomically in a defined pattern. Therefore, a nasal NSAID would readily reach the region of the brain where it acts therapeutically.
PURPOSE:To obtain a cosmetic having excellent quality characteristics in addition to sufficient antistatic properties. CONSTITUTION:At least either one in spongy powder and spongy fiber surface- treated with a hydrophobic agent is blended in cosmetic. As the spongy powder, powder having &lt;=15mum average particle diameter and &lt;=50mum maximum diameter is preferably adopted. As the spongy fiber, a fiber having 0.1-5.0mm fiber length is preferably adopted. Fine-particle or fibrous crushed material obtained by crushing a spongy tissue has action capable of preventing charge of pigment or powder as well as action capable of improving fitness with oily content, action capable of shielding ultraviolet rays and action (antibacterial properties) capable of suppressing proliferation, etc., of bacteria. The crushed material of the spongy tissue is compounded in the cosmetic to provide the object cosmetic having excellent quality characteristics.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic preparation giving a good impression at use and its manufacturing method.  &lt;P&gt;SOLUTION: The cosmetic preparation contains an extract from a plant belonging to Saussurea spp., especially an extract from at least one plant chosen from the group consisting of Saussurea involucrate (Kar. et Kir.) Sch. Blp., Saussurea medusa Maxim. and Saussurea laniceps Hand. -Mazz. and mineral-containing water, especially water obtained by passing purified water through an active water tank filled with minerals or water containing at least 20 ppb sodium, 5 ppb potassium, 10 ppb calcium and 1 ppb magnesium as mineral components. In the manufacturing method of the cosmetic preparation, the mineral-containing water is prepared by passing the purified water through the active water tank filled with various minerals.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide biodegradable shape memory polymer compositions and products thereof and to provide a method for preparing those and a method for using those.  &lt;P&gt;SOLUTION: In one embodiment, the compositions include at least one hard segment and at least one soft segment. The T&lt;SB&gt;trans&lt;/SB&gt;of the hard segment is preferably between -30 and 270°C. At least one of the hard or soft segments can contain a cross-linkable group, and the segments can be linked by formation of an interpenetrating network or a semi-interpenetrating network, or by physical interactions of the segments. Objects can be formed into a given shape at a temperature above the T&lt;SB&gt;trans&lt;/SB&gt;of the hard segment, and cooled to a temperature below the T&lt;SB&gt;trans&lt;/SB&gt;of the soft segment and fixed.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a polymerization initiator composition that exhibits neither burn nor ignitability even in contact with paper or the like in air, provides a polymerizable composition with polymerization activity and cures the polymerizable composition in a short time and an adhesive composition comprising the same.  &lt;P&gt;SOLUTION: The polymerization initiator composition for a polymerizable monomer constituting a dental adhesive composition comprises 100 parts wt. of at least one kind of an organoboron compound (A) selected from the group consisting of a trialkylboron, an alkoxyalkylboron, a dialkylborane and a partially oxidized trialkylboron, 5-40 parts wt. of an aprotic solvent (B) having 50°C-120°C boiling point and 0.2-5 parts wt. of an alcohol (C) having 60°C-180°C boiling point.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The present invention relates the treatment of latent virus infection. A pharmacological and specific inhibitor of FOXO1, the AS1842856 compound, has been used both in vitro and in vivo to uncover the role of FOXO1 in various cellular models (14–20). Using this drug the inventors were able to show that FOXO1 inhibition alone was sufficient to trigger a G0→G1 transition of human peripheral blood T cells (PBT) upstream of the R restriction point of the cell cycle leading to a reactivation of the latent T cells. This transition was characterized by a parallel increase in cell size, metabolic activity and RNA synthesis. The inventors also showed that FOXO1 inhibition was accompanied by the inactivation of the SAMHD1 HIV restriction factor together with a permissiveness of resting human CD4+ T cells to lentiviral infection. They finally demonstrated using HIV-1 latency models that the drug reactivates HIV-1 provirus. Thus, the present invention relates to a FOXO1 inhibitor reactivating latent viruses in host-cell reservoirs for use in the treatment of latent viruses&#39; infection in a subject in need thereof.